Darlene has a wealth of international experience in the biotechnology and pharmaceutical industries, a longstanding track record of raising capital in both private and public equity markets, and of strategic M&A. Her recent executive positions include acting CFO of Normunity and Greywolf Therapeutics. Prior Darlene was CFO of F-star Therapeutics where she led a successful Nasdaq listing, follow-on public offering and all-cash sale of the Company in 2023.
Prior to F-star Therapeutics, Darlene held senior leadership roles in biotech, pharmaceutical, therapeutics, and medical device companies based in the US and Europe. In addition to senior leadership, CFO and board roles she has extensive experience supporting companies through initial public offerings, major capital raises, strategic partnerships, and M&A transactions.
She has served as a board member and audit committee chair since 2006, has held board and committee roles at multiple companies, and currently serves on the boards of Aldeyra Therapeutics (Nasdaq:ALDX) and Lytix Biopharma (Euronext Growth:LYTIX).